What is the India’s rank in the Biopharmaceutical Competitiveness & Investment (BCI) Survey?

India has been ranked 19th out of 28 nations in the Biopharmaceutical Competitiveness & Investment (BCI) Survey, with an overall score of 59 out of 100. India scores low on almost all metrics except for partial step-ups on two counts: scientific capabilities and infrastructure, and clinical research conditions and framework. The list has topped by United States, followed by UK and Switzerland. The ranking is part of the 3rd edition of the BCI commissioned by the Pharmaceutical Research and Manufacturers of America and executed by the Pugatch Consilium. It looks at biomedical innovation and its influencers, like intellectual property protection for investments in the sector.